Latest & greatest articles for methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylphenidate

1. Methylphenidate

. Methylphenidate (also known as Ritalin ®) is a drug that is used in the treatment of attention deficit / hyperactivity disorder (ADHD) in children, adolescents and adults. Modafinil ( Vigil ®) is a drug used in the treatment of narcolepsy (sleeping sickness). In the study. These substances are given in the study only once and in the dosages in which is also 2014 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK. (...) Methylphenidate Top results for methylphenidate - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3

2018 Trip Latest and Greatest

2. Methylphenidate hcl (Foquest)

Methylphenidate hcl (Foquest) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing the Clinical

2020 Health Canada - drugs and medical devices

3. Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects

Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Prescrire IN ENGLISH - Spotlight ''Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects'', 1 June 2019 {1} {1} {1} | | > > > Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects FEATURED REVIEW Methylphenidate is an amphetamine-like psychostimulant used in attention deficit hyperactivity disorder (ADHD). Recent studies have revealed important data about the consequences of in utero exposure

2019 Prescrire

4. Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. Full Text available with Trip Pro

Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with high prevalence in adulthood. There is a recognized need to assess the efficacy of psychotherapy in adult ADHD.To evaluate the efficacy of cognitive behavioral group psychotherapy (GPT) compared with individual clinical management (...) (CM) and that of methylphenidate hydrochloride compared with placebo.Prospective, multicenter, randomized clinical trial of 18- to 58-year-old outpatients with ADHD from 7 German study centers. Patients were recruited between January 2007 and August 2010, treatment was finalized in August 2011, and final follow-up assessments occurred in March 2013.Sessions of GPT and CM were held weekly for the first 12 weeks and monthly thereafter (9 months). Patients received either methylphenidate or placebo

2015 JAMA psychiatry Controlled trial quality: predicted high

5. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder Article Text Methods

2017 Evidence-Based Medicine

6. The Time Course of Effect of Multilayer-Release Methylphenidate Hydrochloride Capsules: A Randomized, Double-Blind Study of Adults With ADHD in a Simulated Adult Workplace Environment. (Abstract)

The Time Course of Effect of Multilayer-Release Methylphenidate Hydrochloride Capsules: A Randomized, Double-Blind Study of Adults With ADHD in a Simulated Adult Workplace Environment. The aim of this study is to assess the onset and duration of efficacy of multilayer-release methylphenidate (PRC-063) over 16 hr compared with placebo in adults with ADHD using the simulated adult workplace environment.After dose-optimization with PRC-063, participants entered a double-blind, placebo-controlled

2016 Journal of attention disorders Controlled trial quality: predicted high

7. Can methylphenidate be used for adults with attention deficit hyperactivity disorder (ADHD)?

Can methylphenidate be used for adults with attention deficit hyperactivity disorder (ADHD)? application/msword

2017 Specialist Pharmacy Services

8. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

9. The efficacy of Ritalin in ADHD children under neurofeedback training. (Abstract)

The efficacy of Ritalin in ADHD children under neurofeedback training. Current research has shown that neurofeedback (NF) is a viable treatment for attention deficit hyperactivity disorder (ADHD), however having pharmacological approach alongside such stimulants is still inevitable. Therefore, the purpose of this study is the comparison of neurofeedback with Ritalin and without Ritalin in treating children with ADHD. This study was causal-comparative in design. Participants were children aged 5 (...) -10 years with ADHD; seven participants were in neurofeedback group with Ritalin and seven in neurofeedback without Ritalin group according to random split and parent's conformation. Clinical Q, Conner's continuous performance test (CPT), and WISC-R were used before and after treatment. For analyzing data, we used descriptive statistical and Mann Whitney U tests. Results showed that even if the two groups were modified in all components, modifications of commission and reaction time of the CPT

2019 Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology Controlled trial quality: uncertain

10. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study (Abstract)

Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use.Ninety-four children and adolescents (ages 8-18 years) who had been (...) treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo. The primary outcome measure was the investigator-rated ADHD Rating Scale (ADHD-RS); secondary outcome measures were the investigator-rated Clinical Global Impressions improvement scale (CGI-I) and the Conners' Teacher Rating Scale-Revised: Short

2019 EvidenceUpdates

11. Sustained effects of neurofeedback and methylphenidate in ADHD children: meta-analysis

Sustained effects of neurofeedback and methylphenidate in ADHD children: meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

12. Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity

Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity (METHACAN) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2018 Clinical Trials

13. Combined methylphenidate and citalopram may help older people with depression recover faster

Combined methylphenidate and citalopram may help older people with depression recover faster Methylphenidate and citalopram for geriatric depression Search National Elf Service Search National Elf Service » » » » Combined methylphenidate and citalopram may help older people with depression recover faster Aug 19 2015 Posted by Depression is not the same across the life course, and we still don’t know which treatments work best for different people. There is that older people with depression (...) don’t respond as well to antidepressants as younger patients, so looking for ways of increasing the efficacy of treatments is a worthwhile effort. The study I’ll be blogging about today was published recently in the American Journal of Psychiatry and investigated the use of combined methylphenidate and citalopram for geriatric depression: Methylphenidate may be familiar as a licensed treatment for ADHD in children. It works by inhibiting dopamine reuptake. Citalopram is an antidepressant that works

2015 The Mental Elf

14. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Full Text available with Trip Pro

Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Hardy SE CRD summary The review did not find definitive evidence (...) of effectiveness of methylphenidate in medically ill older adults with depression, fatigue or apathy, although it appeared to be tolerated in the short term. Due to variation in outcomes, methodological flaws in the included studies and shortcomings in the review process, the reliability of the author's conclusions is not clear. Authors' objectives To assess the efficacy and tolerability of methylphenidate for the treatment of depressive symptoms, fatigue and apathy in medically ill older adults and adults

2009 DARE.

15. Expectation effects on brain dopamine responses to methylphenidate in cocaine use disorder. Full Text available with Trip Pro

Expectation effects on brain dopamine responses to methylphenidate in cocaine use disorder. The response to drugs of abuse is affected by expectation, which is modulated in part by dopamine (DA), which encodes for a reward prediction error. Here we assessed the effect of expectation on methylphenidate (MP)-induced striatal DA changes in 23 participants with an active cocaine use disorder (CUD) and 23 healthy controls (HC) using [11C]raclopride and PET both after placebo (PL) and after MP (0.5

2019 Translational psychiatry Controlled trial quality: uncertain

16. Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD. Full Text available with Trip Pro

Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD. Neurofeedback (NF) has gained increasing interest among non-pharmacological treatments for Attention Deficit Hyperactivity Disorder (ADHD). NF training aims to enhance self-regulation of brain activities. The goal of the NEWROFEED study is to assess the efficacy of a new personalized NF training device, using two different protocols according (...) to each child's electroencephalographic pattern, and designed for use at home. This study is a non-inferiority trial comparing NF to methylphenidate.The study is a prospective, multicentre, randomized, reference drug-controlled trial. One hundred seventy-nine children with ADHD, aged 7 to 13 years will be recruited in 13 clinical centres from 5 European countries. Subjects will be randomized to two groups: NF group (Neurofeedback Training Group) and MPH group (Methylphenidate group). Outcome measures

2019 BMC Psychiatry Controlled trial quality: uncertain

17. Methylphenidate: adverse cardiovascular effects

Methylphenidate: adverse cardiovascular effects Prescrire IN ENGLISH - Spotlight ''Methylphenidate: adverse cardiovascular effects '', 1 June 2015 {1} {1} {1} | | > > > Methylphenidate: adverse cardiovascular effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Methylphenidate: adverse cardiovascular effects Methylphenidate (Ritalin° and other (...) brands) exposes patients to severe adverse effects. It should only be envisaged in cases of severe behavioural disorder, at the minimum effective dose and under supervision. Methylphenidate is prescribed for hyperactive children with attention deficit disorder and in some cases of narcolepsy (uncontrollable tendency to fall asleep). Its adverse effects include neuropsychological and cardiovascular disorders, retarded growth in children, abuse and dependence. Methylphenidate belongs to the family

2015 Prescrire

18. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model (...) of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R Citation King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate

2006 Health Technology Assessment (HTA) Database.

19. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model (...) of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R CRD summary This review concluded that drug treatment was more effective than no drug treatment, but there was insufficient evidence to compare different drugs for effectiveness or safety. This was a well-conducted review

2006 DARE.

20. Methylphenidate enhances implicit learning in healthy adults. Full Text available with Trip Pro

is sensitive to the effects of methylphenidate (Ritalin) in healthy volunteers.Eighty healthy volunteers were randomised to receive either a single (10 mg) dose of methylphenidate or matched placebo. Participants completed a battery of tasks measuring implicit cognition (location priming, contextual cueing, implicit task switching). The effect of methylphenidate on standard, explicit measures of cognition was also assessed.Methylphenidate enhanced implicit learning on the location priming task (...) Methylphenidate enhances implicit learning in healthy adults. One limiting factor in the development of pharmacological interventions to enhance cognition is the absence of biomarkers that can be used in healthy volunteers to screen novel compounds. Drug discovery has tended to rely heavily on explicit measures of cognition, but these are typically insensitive to cognition-enhancing effects in healthy volunteers. This study investigated whether a novel battery of implicit cognition measures

2018 Journal of psychopharmacology (Oxford, England) Controlled trial quality: uncertain